Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced…

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer • Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36),

Event · Clinical / regulatory
Product
PIKTOR
Milestone
topline data
Indication
advanced endometrioid endometrial cancer

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 9, 2026, 12:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$FTH
Bullish
high confidence
Mentioned
$FTH
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FTHBullishHigh
01

Why it matters

The disclosed data provide the first efficacy signal for PIKTOR in endometrial cancer, supporting advancement to a pivotal Phase 3 trial and potentially unlocking significant market value.

02

Market read

Positive Phase 2 data are likely to drive short‑term upside for FTH and may influence valuation of comparable PI3K pathway assets.

03

What to watch

Safety signals such as hyperglycemia and stomatitis, though low‑grade, may affect long‑term tolerability perception.

Relevance 9/10Novelty 9/10Timing: today, following the webcast release

Background

Faeth Therapeutics (Nasdaq: FTH) is a clinical‑stage biotech focused on multi‑node inhibition of oncogenic pathways. Its lead program PIKTOR combines serabelisib and sapanisertib with paclitaxel.

Company-level read

Ticker impact

$FTHBullishHigh confidence
Context

Faeth Therapeutics disclosed positive Phase 2 topline results for its PIKTOR plus paclitaxel regimen in advanced endometrial cancer.

Expected impact

upward pressure as the market prices in higher valuation expectations for PIKTOR.

Evidence & confidence

The 33% confirmed ORR and 7.4‑month median PFS exceed typical salvage therapy benchmarks, suggesting a differentiated asset that could drive future revenue.

Market effects

Strengthens the broader PI3K/AKT/mTOR oncology pipeline, potentially boosting peer biotech valuations.

US biotech sector may see modest gains as investors rotate into late‑stage oncology plays.

Limited to biotech investors; no immediate macro impact.

Counterpoint

If the Phase 3 fails to confirm these results, the current rally could reverse sharply.

Key entities

  • Faeth Therapeutics, Inc.

    Clinical‑stage biotech developing PIKTOR.

  • Anand Parikh

    Co‑Founder and CEO of Faeth, presented the data.

  • The GOG Foundation

    Collaborates on the Phase 2 trial.

Related articles

$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

$FTHMed

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.